The FDA has no sway over Mexico or any other country evaluating leronlimab. The fact that the Mexico trial is 25 patients tells me they are expediting this...and with good reason. The FDA has too many interests beyond the patient for me to worry much about what they do. If it’s approved in the US first, great! If not, and they delay for some perceived reason other than what’s in the best interest of the patient, shame on them. Looking at the current therapeutic agents being used, leronlimab has a low bar to provide improvements in care. IMO